Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer
Table 1
Frequency of clinicopathological characteristics.
Variables
N (%)
Age
62.99 ± 10.42
Gender
Male
225 (79.5)
Female
58 (20.5)
Group of 4
EAC
84 (29.7)
nEAC
117 (41.3)
ESCC
32 (11.3)
nESCC
50 (17.7)
Neoadjuvant treatment
Yes
167 (59.0)
No
116 (41.0)
Adjuvant treatment
Yes
30 (10.6)
No
253 (89.4)
Depth of tumor
pT0/ypT0
1 (0.4)/13 (4.6)
pTis/ypTis
3 (1.1)/1 (0.4)
pT1/ypT1
58 (20.5)/17 (6.0)
pT2/ypT2
21 (7.4)/29 (10.2)
pT3/ypT3
25 (8.8)/94 (33.2)
pT4/ypT4
4 (1.4)/8 (2.8)
pTx/ypTx
4 (1.4)/5 (1.8)
Nodal stage
pN0/ypN0
77 (27.2)/70 (24.6)
pN1/ypN1
35 (12.3)/75 (26.5)
pN2/ypN2
1 (0.4)/9 (3.2)
pN3/ypN3
2 (0.8)/13 (4.6)
pNx/ypNx
1 (0.4)/0 (0.0)
Tumor grading
G1
13 (4.6)
G2
125 (44.2)
G3
117 (41.3)
G4
25 (8.8)
Gx
3 (1.1)
UICC stage
0
27 (9.5)
1
75 (26.5)
2
80 (28.3)
3
97 (34.3)
4
4 (1.4)
Surgical approach
One-stage
233 (82.3)
Two-stage
50 (17.7)
Age is reported as the mean ± SD. EAC: esophageal adenocarcinoma; nEAC: neoadjuvant-treated esophageal cancer; ESCC: esophageal squamous cell carcinoma; nESCC: neoadjuvant-treated esophageal squamous cell carcinoma; UICC: Union for International Cancer Control.
